Arrhythmias, Cardiac, Brain Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Prostatic Cancer, Spinal Neoplasm
Conditions
Keywords
Radiation Therapy, markerless tracking
Brief summary
This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.
Detailed description
This observational study will access routinely acquired radiation therapy treatment data from 300 patients including brain, breast, head and neck, kidney, liver, pancreas, prostate, spine and cardiac anatomic sites. At least 30 patients will be recruited from each anatomic site to enable sufficient data for the markerless tracking method training, testing and validation. The clinical data will be used to develop, train, test and validate a markerless target tracking method. After the treatment, the ground truth and the variability in the ground truth will be computed. The patient images, the markerless tracking results, the ground truth and the variability will be uploaded to an in-house developed clinical trial learning system. Uploading additional data to the learning system automatically triggers the model building of the deep learning system. In this manner, the learning system gets both more accurate and more robust with each patient accrued. As the patient data accrues, the primary hypothesis of targeting accuracy can be tested. The developed markerless tracking software will be applied by study personnel to the treatment imaging data for each anatomic site using five-fold cross-validation where 80% of the data is used for training and the remaining unseen 20% of the data is used for testing. Target positions produced by the markerless tracking will be compared with a 'ground truth'.
Interventions
None listed
Sponsors
University of Sydney
Princess Alexandra Hospital, Brisbane, Australia
Calvary Mater Newcastle, Australia
Western Sydney Local Health District
Austin Health
Peter MacCallum Cancer Centre, Australia
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre. * Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy. * Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites. * Provides written informed consent.
Exclusion criteria
* Less than 18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy of markerless tracking | 3 years | Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical acceptability of markerless tracking system | 3 years | Proportion of radiation therapists considering the markerless tracking system acceptable using a survey |
Countries
Australia
Contacts
CONTACTShona Silvester
STUDY_CHAIRPaul Keall
Professor
Outcome results
None listed